NCT06596200尚未招募4 期
Pilot Study for the Use of Spinal Cord Stimulation to Alleviate Pain from Chemotherapy Induced Peripheral Neuropathy Due to Taxane or Platinum Based Agents
适应症
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 入组人数
- 10
- 主要终点
- -- Measure response of CIPN pain to HF10 treatment using the numeric scale of pain (NRS) at SCS trial for all subjects and at 3, 6 and 12 months after implant for subjects who qualify for permanent implant.
研究概览
简要总结
Spinal Cord Stimulation using 10 kHz stimulation to the thoracic spinal cord will be a safe and effective treatment for CIPN, reducing pain in the lower extremities by at least 50%.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •CIPN as diagnosed by Oncology and/or neurology
- •Receipt of a platinum-based or taxane chemotherapy prior to development of CIPN
- •Pain severity greater than 4 out of 10 on a numeric rating scale of pain
- •Pain chronicity greater than 6 months after the cessation of chemotherapy
- •Failure of medical therapy, which must have included duloxetine
- •Age 18 or greater
排除标准
- •Platelet count less than 100k/mm3
- •Spinal anatomy precluding placement of the SCS leads between T6 and T11
- •Active infection
- •Estimated Lifespan less than 1 year
- •Receipt of vincristine, thalidomide, bortezomib, or eribulin within the prior 12 months
结局指标
主要结局
-- Measure response of CIPN pain to HF10 treatment using the numeric scale of pain (NRS) at SCS trial for all subjects and at 3, 6 and 12 months after implant for subjects who qualify for permanent implant.
时间窗: 1 year
次要结局
- - - Neuropathy symptoms will be quantified using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-CIPN twenty-item scale (CIPN20). CIPN20 is a 20-item patient questionnaire with items scored 1 to 4.(1 year)
- - Pain interference in daily life will be quantified via the brief pain inventory (BPI).(1 year)
- - Neuropathy findings will be quantified with the modified Toronto clinical neuropathy score (mTCNS).(1 year)
- - The subject's impression of SCS efficacy will be measured using the patient global impression of change (PGIC).(1 year)
- - Health related quality of life will be assessed using the EuroQOL5D-5L questionnaire.(1 year)
- - Any treatment related adverse events observed during the trial will be documented using the Common Terminology Criteria for Adverse Events (CTCAE) ver 5.0.(1 year)
研究者
相似试验
已完成
不适用
Spinal Cord Stimulation in Chemotherapy Induced NeuropathyChemotherapy-induced Peripheral NeuropathyNCT03764514Prisma Health-Upstate5
已完成
1 期
Spinal Cord Stimulation for the Treatment of Major Depressive DisorderMajor Depressive DisorderNCT03433339University of Cincinnati20
Unknown
不适用
Efficacy and Safety of Spinal Cord Stimulation in Patients With Chronic Intractable PainPainChronic PainBack PainSpinal Cord StimulationNervous System DiseasesNCT03858790Beijing Pins Medical Co., Ltd54
进行中(未招募)
不适用
Brain Controlled Spinal Cord Stimulation In Participants With Spinal Cord Injury For Lower Limb RehabilitationSpinal Cord InjuriesParaplegiaNCT06243952Ecole Polytechnique Fédérale de Lausanne3
招募中
不适用
Non-invasive Spinal Cord Stimulation for Recovery of Autonomic Function After Spinal Cord InjuryAutonomic DysfunctionSpinal Cord InjuryAutonomic DysfunctionSexual DysfunctionOrthostatic HypotensionNCT05369520University of British Columbia30
